Clopidogrel Tablet, Film Coated
Product Images NDC 72789-469

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 72789-469). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789469 Label (72789469)

This is a medicine label for Clopidogrel tablets containing 75 mg, with a total of 90 tablets. The expiration date is 07/2026. Patients are advised to consult their doctor for side effects and can report them to the FDA. The tablets should be taken a certain number of times per day. Each tablet contains 97.875 mg of clopidogrel bisulfate (equivalent to 75 mg of clopidogrel base). The dispensing should include a Medication Guide for each patient. The label includes contact information for the pharmaceutical company PD-Rx in Okahoma City.*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

This text provides information on the exposure to the Clopidogrel active metabolite following multiple doses of Clopidogrel 75 mg alone or with Proton Pump Inhibitors (PPIs). It includes a comparison of the effect of different PPIs such as Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole on the active metabolite AUC. The data also presents the mean and 90% confidence intervals for each PPI.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

This text provides a comparison of the cumulative event rates (%) over time for cardiovascular death, myocardial infarction, and stroke between patients taking placebo with aspirin and patients taking clopidogrel with aspirin. The data shows a significant difference between the two groups with a p-value of 0.00009. The chart displays the percentages over various months of follow-up.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

This is not readable.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

This text provides statistical information on the efficacy of Clopidogrel compared to a Placebo in reducing the risk of death before the first discharge. The data shows that Clopidogrel resulted in 7.5% deaths compared to 8.1% in the Placebo group, indicating a 7% proportional risk reduction with a significance level of p=0.03. The data is based on observations up to 28 days since randomization.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

This text appears to be a comparison of the effectiveness of Clopidogrel versus a placebo in reducing the risk of certain events. Clopidogrel shows a 9% proportional risk reduction compared to the placebo group, with a 7% decrease in death and a reduction in re-infarction or stroke occurrences before discharge. The data seems to track the number of events among participants over a period of up to 28 days since randomization.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

This text provides information on the comparison between the use of Clopidogrel and Placebo in different subgroups based on gender, age, time since onset, blood pressure, heart rate, and whether a fibrinolytic agent was given. The table shows the number and percentage of participants favoring Clopidogrel or Placebo in each subgroup, allowing for an evaluation of the effects across different demographics and conditions. The text also mentions Odds Ratio with a 99% confidence interval for further analysis.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

This is a table displaying the cumulative event rate (%) for fatal or non-fatal vascular events over the course of 36 months of follow-up for two medications: Aspirin and Clopidogrel. The data provides information on the event rates at 6, 12, 18, 24, 30, and 36 months for both medications.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

FDA Label Image

Chemical Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.